Donepezil Hydrochloride
Product Images NDC 63187-401

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 63187-401). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig 1 (0001)

A line graph depicting ADAS-cog change from baseline over 30 weeks of drug treatment comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The y-axis indicates cognitive change with clinical improvement above baseline and clinical decline below. Donepezil groups show improvement over placebo across treatment weeks.*

FDA Label Image

Fig 2 (0002)

A cumulative percentage of patients chart comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and Placebo groups. The x-axis shows change from baseline and the y-axis cumulative percentage of patients. The chart includes data points for changes at -7, -4, and 0 on the ADAS-cog scale, illustrating differences in cognitive change among treatment groups.*

FDA Label Image

Fig 3 (0003)

A bar graph showing patient percentages categorized by CIBIC-plus Rating for Donepezil Hydrochloride at 5 mg/day and 10 mg/day doses compared to placebo. The x-axis lists improvement and worsening categories, while the y-axis shows the percentage of patients. The highest percentages are in the 'No Change' and 'Minimally Worse' categories across all groups.*

FDA Label Image

Fig 4 (0004)

A line graph depicting ADAS-cog change from baseline over weeks of drug treatment and placebo phase. It compares clinical improvement and decline for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups, showing mean change with standard error bars over a 12-week treatment period and subsequent placebo phase.*

FDA Label Image

Fig 5 (0005)

A cumulative percentage of patients chart comparing changes from baseline in ADAS-cog scores among Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups. The x-axis represents change from baseline, and the y-axis shows cumulative patient percentage. The chart includes reference lines for 7 points, 4 points, and no change, with a table summarizing percentage changes for each treatment group.*

FDA Label Image

Fig 6 (0006)

A bar chart showing the distribution of patients by CIBIC-plus Rating categories comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The chart depicts percentages of patients across categories from Markedly Improved to Markedly Worse, highlighting relative patient outcomes for each treatment group.*

FDA Label Image

Fig 7 (0007)

A line graph showing SIB (Severe Impairment Battery) change from baseline over 6 months of drug treatment comparing Donepezil Hydrochloride 10 mg/day and placebo. The graph depicts clinical improvement and decline on the vertical axis and months of treatment on the horizontal axis, illustrating results with error bars for mean ± SE.*

FDA Label Image

Fig 8 (0008)

A cumulative percentage plot showing the distribution of SIB (Severe Impairment Battery) score changes from baseline in patients. The graph compares Donepezil Hydrochloride 10 mg/day versus placebo, with SIB Change from Baseline on the x-axis and cumulative percentage of patients on the y-axis.*

FDA Label Image

Fig 9 (0009)

A line graph showing the ADCS-ADL change from baseline over 6 months for Donepezil Hydrochloride 10 mg/day compared to placebo. The y-axis measures mean change from baseline in ADCS-ADL, with clinical improvement indicated upward and clinical decline downward. The x-axis shows months of drug treatment at 0, 3, and 6 months. Donepezil Hydrochloride shows less decline over time versus placebo.*

FDA Label Image

Fig 10 (0010)

A line graph showing the cumulative percentage of patients versus ADCS-ADL change from baseline. It compares Donepezil Hydrochloride 10 mg/day with a placebo group, with data points indicated by solid circles for Donepezil and open squares for placebo.*

FDA Label Image

Fig 11 (0011)

A line graph depicting clinical change from baseline (SIB Change from Baseline LS Mean ± SE) over 24 weeks of drug treatment with Donepezil Hydrochloride at dosages of 10 mg/day and 23 mg/day. The vertical axis shows clinical improvement and decline, while the horizontal axis represents weeks of treatment. The 23 mg/day dosage shows greater clinical improvement over time compared to the 10 mg/day dosage.*

FDA Label Image

Fig 12 (0012)

A cumulative percentage plot depicting patients' response to Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day. The x-axis shows the change from baseline in SIB (Severe Impairment Battery) scores, while the y-axis indicates the cumulative percentage of patients. The graph compares dose-related response distributions.*

FDA Label Image

Fig 13 (0013)

Bar graph comparing the percentage of patients under two dosage levels of Donepezil Hydrochloride, 23 mg/day and 10 mg/day, across categories of patient response ranging from markedly improved to markedly worse. The graph displays patient distribution percentages for each response category for both dosages.*

FDA Label Image

Donepezil Hydrochloride (Donepezil Hydrochloride)

Chemical structure of donepezil hydrochloride, showing the molecular connectivity including methoxy groups, piperidine ring, phenyl ring, and associated hydrochloride component.*

FDA Label Image

Donepezil 10mg (Donepezil Hydrocloride 5 mg)

Donepezil HCl 10mg tablets label for a 30-count package by Proficient Rx LP. The film-coated tablets are described as white to off-white, round, debossed with "J" on one side and "10" on the other. Manufactured by Jubilant Life Sciences Limited, India, with storage instructions at 20°-25°C (68°-77°F). Additional smaller labels show lot, expiration, and serial number placeholders.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.